Caxton Associates (New York)’s Prelude Therapeutics PRLD Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-65,453	Closed	-$395K	–	595
2022 Q4	$395K	Sell	65,453 -20,539	-24%	-$124K	0.03%	269
2022 Q3	$568K	Buy	85,992 +2,125	+3%	+$14K	0.08%	201
2022 Q2	$438K	Buy	+83,867	New	+$438K	0.04%	292